NEW DELHI: The healthcare and pharma sector saw an overall 64 deals, valued at $2.8 billion in Q3 of 2024, marking the sector's highest quarterly volumes in three years, according to a report on Tuesday.
The report by Grant Thornton Bharat showed that mergers and acquisitions, and private equity deal volumes increased significantly, with 59 deals worth $2.2 billion, the highest since Q4 2021.
However, Q3 2024 saw a 47 per cent decline in deal values compared to Q2 2024.
The decline was mainly due to fewer high-value deals, with only two deals worth $1.8 billion.
In contrast, Q2 2024 had 11 high-value deals (over $100 million) totalling $3.4 billion.
Healthtech, Pharma, and biotech and wellness segments led the deal volumes collectively with a 66 per cent share, while Pharma and biotech led the deal values with a 79 per cent share.
“Overall, the pharma and healthcare sector witnessed increasing investor interest, driven by strong consumer demand focused on healthy living, innovation, and a focus on high-growth areas like biologics and specialty care, ” Bhanu Prakash Kalmath S J, Partner and Healthcare Services Industry Leader, Grant Thornton Bharat.
“We anticipate the deal momentum to continue as companies position for growth both domestically and globally, ” he added.
The report said that Q3 2024 saw 26 merger and acquisition deals valued at $1.9 billion, achieving record-high quarterly deal volumes.
Deal volumes also increased 44 per cent from Q2 2024, and deal values rose by 39 per cent to $1.9 billion.
Further, Q3 2024 saw 33 private equity/venture capital deals valued at $246 million. Deal values declined 91 per cent from Q2 2024 due to the absence of big-ticket transactions.
The Q3 2024 also saw two IPOs valued at $459 million, among the largest in the sector for 2024, while three QIPs raised $214 million, marking a significant increase in activity.